
Nextcure (NXTC) Stock Forecast & Price Target
Nextcure (NXTC) Analyst Ratings
Bulls say
NextCure Inc has secured global rights to SIM0505 outside Greater China, with the potential for up to $745 million in upfront and milestone payments, alongside tiered royalties that could reach double-digit percentages on net sales. Recent preclinical data revealed promising anti-tumor efficacy across various solid tumor models and indicated a favorable safety profile, supporting the company's pipeline of cancer immunomedicines. Additionally, NextCure's strategy to advance multiple clinical and preclinical programs, including ADCs and partnerships for ongoing trials, positions the company for significant future growth in the biopharmaceutical market.
Bears say
NextCure Inc has seen a significant reduction in its projected enterprise value, now estimated at $37.5 million, down from a previous valuation of $75 million. This decline has led to a decrease in the projected price target to $15, reflecting concerns about the company's ability to successfully advance its therapies in clinical settings. Additionally, the potential failure of NextCure's therapies in clinical trials poses a substantial risk to the company's financial outlook and overall market confidence.
This aggregate rating is based on analysts' research of Nextcure and is not a guaranteed prediction by Public.com or investment advice.
Nextcure (NXTC) Analyst Forecast & Price Prediction
Start investing in Nextcure (NXTC)
Order type
Buy in
Order amount
Est. shares
0 shares